Healius Ltd
ASX:HLS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.7
1.515
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HLS stock under the Base Case scenario is 3.068 AUD. Compared to the current market price of 0.975 AUD, Healius Ltd is Undervalued by 68%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Healius Ltd.
| US |
|
CVS Health Corp
NYSE:CVS
|
|
| US |
|
Cigna Corp
NYSE:CI
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Healius’s heavy reliance on government reimbursements for pathology and diagnostic imaging services poses a significant risk if future Medicare policy changes or cuts reduce revenue streams.
Increasing competition from Sonic Healthcare and other private pathology operators could pressure Healius’s pricing power and reduce its market share, especially if bulk-billing rates come under scrutiny.
Delays or challenges in successfully integrating and optimizing its newly restructured day hospital and diagnostic centers could weaken Healius’s broader service offering, leading to slower growth than anticipated.
Healius’s strong position in the Australian pathology sector, combined with cost optimization efforts, could yield competitive margins and sustainable growth even if parts of the healthcare budget tighten.
The company’s pivot away from large-scale medical centers toward more specialized day hospitals aligns with rising demand for short-stay procedures and can capture a larger pool of private patients.
Its extensive geographic footprint and recognized service quality give Healius an opportunity to cross-sell integrated healthcare services (pathology, imaging, and day hospitals), underpinning stronger patient retention and profitability.
Revenue & Expenses Breakdown
Healius Ltd
Balance Sheet Decomposition
Healius Ltd
| Current Assets | 251.9m |
| Cash & Short-Term Investments | 57.2m |
| Receivables | 164.9m |
| Other Current Assets | 29.8m |
| Non-Current Assets | 1.5B |
| Long-Term Investments | 3.2m |
| PP&E | 938.5m |
| Intangibles | 486.6m |
| Other Non-Current Assets | 96.8m |
| Current Liabilities | 446.2m |
| Accounts Payable | 133.9m |
| Other Current Liabilities | 312.3m |
| Non-Current Liabilities | 742.9m |
| Long-Term Debt | 730.5m |
| Other Non-Current Liabilities | 12.4m |
Free Cash Flow Analysis
Healius Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Healius Ltd
|
Revenue
|
1.3B
AUD
|
|
Cost of Revenue
|
-214m
AUD
|
|
Gross Profit
|
1.1B
AUD
|
|
Operating Expenses
|
-1.1B
AUD
|
|
Operating Income
|
200k
AUD
|
|
Other Expenses
|
-151.4m
AUD
|
|
Net Income
|
-151.2m
AUD
|
HLS Profitability Score
Profitability Due Diligence
Healius Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Healius Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
HLS Solvency Score
Solvency Due Diligence
Healius Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Healius Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HLS Price Targets Summary
Healius Ltd
According to Wall Street analysts, the average 1-year price target for HLS is 0.836 AUD with a low forecast of 0.606 AUD and a high forecast of 1.103 AUD.
Dividends
Current shareholder yield for HLS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one HLS stock under the Base Case scenario is 3.068 AUD.
Compared to the current market price of 0.975 AUD, Healius Ltd is Undervalued by 68%.